COMBINED CHEMOTHERAPY AND IMMUNOTHERAPY Russian patent published in 2013 - IPC C07K14/47 C07K14/71 A61K39/00 A61P35/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology and medicine, more specifically to the use of EGFRvIII in a combination with temozolomide, and may be used for treating a tumour in an individual. A method of treating the tumour in the individual provides introducing into the individual an amount of temozolomide effectively inducing lymphopenia; monitoring of white blood cell count after introducing temozolomide; and introducing into the individual an effective amount of the EGFRvIII peptide for white blood cell count recovery in a point of the least white blood cell count. Introducing the EGFRvIII peptide into the individual may be combined with introducing the effective amount of GM-CSF as an adjuvant.

EFFECT: invention enables the combined chemotherapy and immunotherapy without downing the immunotherapeutic effects with temozolomide-induced lymphopenia being able to intensify action of a peptide vaccine.

19 cl, 6 ex